Embrace - A European study on MRI-guided brachytherapy in locally advanced cervical cancer
NEWS!   
The 5th Embrace Annual Meeting took place on Friday 17th and Saturday 18th January, 2014 in Vienna, Austria. The presentations are now available in the Meetings section of the Members Info area. Thank you to all who attended. We hope it was an informative, productive and enjoyable use of your time.
1000 Patients!  The 1000th patient was registered on 6th November, 2013.
New Database Variables and CRF: Note that the latest CRF is now available in Excel format in the "Appendix" section. The updated CRF contains all the new variables (e.g. D98 parameters) in compliance with the data entry form. 
What is EMBRACE?

EMBRACE is a study on MRI guided brachytherapy (BT) in locally advanced cervical cancer. Today point-based two-dimensional BT is most often used for definitive radiotherapy in cervical cancer. However, MRI guided 3D brachytherapy is increasingly being used in several centres, and the results reported so far are very promising. The major advantage of this technique is the possibility to conform the dose given by BT with regard to both volume (3D) and time (4D). Thus, by repetitive imaging performed before each BT implant it is possible to adapt the dose given by BT to the anatomy of each individual patient taking into account not only the position of organs at risk but also the tumour regression which often is obtained by preceding external beam radiotherapy and chemotherapy. Based on the experience collected so far, the image based BT approach significantly improves the DVH parameters and the improved dose delivered seems to have a major impact on the clinical outcome with a concomitant decrease in the rates of both local failure and morbidity.

 

The aim of the EMBRACE protocol is to introduce MRI based brachytherapy in a multicenter setting within the frame of a prospective observational study and to correlate image based DVH parameters for the clinical target volume and for organs at risk with outcome. Based on these results, we hope to develop prognostic and predictive statistical models for clinical outcomes including volumetric, dosimetric, clinical and biological risk factors as well as radiobiological parameter estimates that will allow a precise risk assessment in individual patients and aid in the development of new treatment protocols.

 

Patient registration and reporting will be performed via the internet to a central database accessible for registered investigators through this website. The study coordinator are Richard Pötter (Vienna), Jacob Chr. Lindegaard (Aarhus), Kari Tanderup, (Aarhus) and Christian Kirisits (Vienna). If you would like to hear more about the possibilities to participate in this trial, please contact Ian Dilworth at the study office in Vienna.

 

 

Sponsored by:  The Medical University of Vienna
 
Supported by: 
 

Nucletron
Varian
 
Embrace